DRIO
DarioHealth Corp. is a leading, global digital therapeutics company revolutionizing the way people with chronic conditions manage their health. By delivering evidence-based interventions that are driven by data, high-quality software and coaching, the Company empowers individuals to make healthy adjustments to their daily lifestyle choices to improve their overall health. Its cross-functional team operates at the intersection of life sciences, behavioral science and software technology to deliver highly engaging therapeutic interventions. Dario is one of the highest-rated diabetes solutions in the market, and its user-centric MyDario™mobile app is loved by tens of thousands of consumers around the globe. DarioHealth is rapidly moving into new chronic conditions and geographic markets, using a performance-based approach to improve the health of users managing chronic disease.
DarioHealth Corp. (DRIO) is rated C+ (2.5/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Profitability (B-); its weakest is Momentum (D-). The rating has held at C+ for 7 weeks.
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-11 | B- (3.0) | B- (2.9) | B- (3.1) | D- (1.0) | C+ (2.6) | C+ (2.5) |
| 2026-11-04 | B- (3.0) | B- (2.9) | B- (3.1) | D (1.2) | C+ (2.7) | C+ (2.6) |
| 2026-10-28 | B- (3.0) | C+ (2.8) | B- (3.1) | D (1.5) | C+ (2.7) | C+ (2.6) |
| 2026-10-21 | B- (3.0) | B- (2.9) | B- (3.1) | D+ (1.6) | C+ (2.6) | C+ (2.6) |
| 2026-10-14 | B- (3.0) | B- (2.9) | B- (3.1) | C (2.2) | C+ (2.6) | C+ (2.8) |